

King's Research Portal

DOI:

[10.1200/JCO.2017.76.3425](https://doi.org/10.1200/JCO.2017.76.3425)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Freeman, S. D., Hills, R. K., Virgo, P., Khan, N., Couzens, S., Dillon, R., Gilkes, A., Upton, L., Nielsen, O. J., Cavenagh, J. D., Jones, G., Khwaja, A., Cahalin, P., Thomas, I., Grimwade, D., Burnett, A. K., & Russell, N. H. (2018). Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 36(15), 1486-1497. <https://doi.org/10.1200/JCO.2017.76.3425>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Standard-Risk Patients Without NPM1 Mutations

Sylvie Freeman¹*, Robert K Hills²*, Paul Virgo³, Naeem Khan¹, Steve Couzens⁴, Richard Dillon⁵, Amanda Gilkes⁶, Laura Upton², Ove Juul Nielsen⁷, James D Cavenagh⁸, Gail Jones⁹, Asim Khwaja¹⁰, Paul Cahalin¹¹, Ian Thomas², David Grimwade^{5†}, Alan K Burnett¹², Nigel H Russell¹³

* These authors contributed equally to this work

Value of MFC-MRD with Response Criteria in AML Risk Groups

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Abstract

Purpose

We investigated the effect on outcome of measurable/minimal residual disease (MRD) status after each induction course in order to evaluate the extent of its predictive value for acute myeloid leukemia (AML) risk groups including *NPM1*wild-type standard-risk when incorporated with other induction response criteria.

Patients and Methods

As part of the NCRI AML17 trial, 2450 younger adult patients with AML or high risk MDS had prospective flow cytometric MRD (MFC-MRD) assessment. Post course-1 (C1) responses were categorised as resistant disease (RD), partial remission (PR) and CR/CRi by clinicians, with CR/CRi subdivided by MFC-MRD assay into MRD+ and MRD-. Patients without high-risk factors, including *Flt3*ITDwild-type/*-NPM1*wild-type subgroup, received a second daunorubicin/ara-C induction; course-2 (C2) was intensified for high-risk.

Results

Survival outcomes from PR and MRD+ responses post-C1 were similar, particularly for good/standard-risk subgroups (5 year OS: 33%RD vs 49%PR vs 51%MRD+ vs 70%MRD-, $p<.0001$). Adjusted analyses confirmed significant OS differences between C1 RD vs PR/MRD+ but not PR vs MRD+. CRi post-C1 reduced OS in MRD+ (19%CRi vs 45%CR, $p=.001$) patients with a smaller effect post-C2.

The prognostic effect of C2 MFC-MRD status (relapse, HR 1.88(1.50- 2.36), $p<0.001$; survival, HR 1.77(1.41-2.22) $p<0.001$) remained significant when adjusting for C1 response. MRD-positivity appeared less discriminatory in poor-risk patients by stratified analyses. For *NPM1*wild-type standard-risk subgroup, C2 MRD+ was significantly associated with poorer outcomes (OS, 32% vs 64%MRD-, $p=0.003$; relapse incidence 89% when MRD+ $\geq 0.1\%$); transplant benefit was more apparent in MRD+(HR 0.72(0.31-1.69) than MRD-(HR 1.68(0.75-3.85); ($p=0.16$ for interaction).

Conclusion MFC-MRD can improve outcome stratification by extending definition of partial response post first induction and may help predict *NPM1*wild-type standard-risk patients with poor outcome who benefit from transplant in CR1.

1 Introduction

2 In acute myeloid leukemia (AML) failure to achieve morphological complete remission (CR) after a
3 first cycle of induction in previously untreated patients is an established independent prognostic
4 factor from earlier studies¹⁻³. Thus morphological response at this time-point is often incorporated
5 with genetic and pre-treatment clinical parameters to guide further therapy⁴, including second
6 induction courses, choice of consolidation and whether intensification from allogeneic stem cell
7 transplantation (SCT) may be appropriate in otherwise intermediate risk patients. Despite
8 morphological response criteria being standard, a different approach for measuring response has
9 been proposed^{5,6} due to the independent prognostic value from measurable/minimal residual
10 disease (MRD) assays when discrepant with morphology⁷⁻⁹ or in CR¹⁰⁻¹² and the equivalent poor
11 outcomes between MRD positivity and active disease pre-myeloablative SCT^{13,14}

12 Previous studies have shown the prognostic value of MRD monitoring by PCR for patients with
13 validated molecular targets, usually after 2 courses of chemotherapy^{11,12,15}. Flow cytometric MRD
14 (MFC-MRD) may identify as early as post course 1, patients with a poorer response despite
15 achieving CR and is an assay that can be applied across AML genetic subgroups^{12,16-20}. There is
16 however insufficient data to ascertain the relative prognostic impact of MFC-MRD positivity in CR
17 post course 1 compared to morphological active disease; it is feasible that the outcomes of
18 patients with detectable MRD resemble those of refractory patients who achieve the cytoreduction
19 criteria for a morphological partial remission^{21,22}. Evaluating this will help refine which response
20 categories are the most useful prognostic surrogate endpoints to assess effectiveness of the first
21 induction course.

22 It is also uncertain for patients who complete a second chemotherapy course whether the quality
23 of response after course 1, with inclusion of MFC- MRD assessment, adds prognostic information
24 to CR-MRD status post course 2. The value of MFC-MRD status to differentiate outcome at either
25 time-point is likely to be heterogeneous between established risk subgroups due to disease,
26 treatment and assay factors but the extent of this has not been established.

27 Treatment decisions, including predicting the benefit of SCT, are particularly challenging for the
28 standard-risk subgroup. MFC-MRD assays are most likely to influence therapeutic choices for
29 *NPM1*-wild type standard-risk patients following recent data that post induction RT-qPCR
30 quantitation of blood mutated transcripts reliably predicts outcome for *NPM1*-mutated patients^{23,24}.
31 There is thus a specific need to define the usefulness of MFC-MRD for risk stratification in this
32 subgroup.

33 In this study we aimed to determine the prognostic effect of MFC-MRD measurement incorporated
34 into response assessment post induction courses for the different risk subgroups, including *NPM1*
35 wild type standard-risk patients, in a large cohort of younger AML patients who had undergone
36 intensive treatment in the National Cancer Research Institute (NCRI) AML17 trial.

Methods

Patients

Patients were enrolled in the NCRI AML17 trial (ISRCTN: 55675535) from April 6, 2009, to December 31, 2014. (A list of treatments is provided in Appendix, [Fig. A1](#)).

The AML17 protocol was designed primarily for younger patients, generally age < 60 years. Patients with high risk myelodysplastic syndrome (MDS), which was defined as >10% marrow blasts at diagnosis, and secondary AML were eligible. Acute promyelocytic leukemia (APML) patients were not included in this MRD study. After first induction, patients were defined by risk of relapse, using a validated score comprising cytogenetics, WBC, age, secondary disease, morphological response to course-1^{25,26} and *FLT-3* ITD/ *NPM1* mutation status.

Morphological-based response criteria were 1) complete response (CR), < 5% blasts in a cellular bone marrow, CRi when best response was with neutropenia <1000/ μ L or thrombocytopenia <100,000/ μ L; 2) partial remission (PR), decrease of pre-treatment bone marrow blast percentage by at least 50% to 5 -15% in a cellular marrow (hematological recovery not required)¹, 3) resistant disease (RD), >15% marrow blasts (patients surviving at least 7 days post completion of treatment). Responses were classified by centers.

Patients designated as favorable or standard-risk received the second daunorubicin/cytosine arabinoside course and were then randomized to receive either 1 or 2 courses of high-dose cytosine arabinoside. High-risk patients were offered a randomization between FLAG-Ida or daunorubicin/clofarabine with the intention of eventually proceeding to allogeneic stem cell transplantation (SCT). *FLT3*-ITD mutant patients were directed to the Lestaurtinib randomisation until 2012.

The trial was sponsored by Cardiff University, approved by Wales-REC3 and conducted in accordance with the Declaration of Helsinki.

Multiparameter Flow Cytometry (MFC) detection of MRD

Samples for MFC-MRD were requested at baseline (bone marrow and/or blood) and following each course (bone marrow). A summary of sample logistics and processing is provided in the Appendix. MFC-MRD analysis was performed centrally, using standardised gating strategy that screened for 'different-from-normal' LAIPs (Leukemia-Associated-Immunophenotypes) on blasts pre-treatment and tracked these (~0.02 -0.05% sensitivity thresholds) but also applied the 'different-to-normal' approach in follow-up (FU) samples to detect changes in blast LAIPs (~0.05 - 0.1% sensitivity threshold). In this study only samples for which there were pre-treatment LAIPs to monitor could be reported as MFC-MRD-negative whilst samples with any level of MRD detected above a diagnostic-LAIP or different-from-normal FU-LAIP threshold were reported as MFC-MRD-positive.

Clinicians were not informed of MFC-MRD results.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Statistical Analysis

All end points were based on the revised criteria of the International Working Group for Diagnosis²¹. Survival percentages were calculated using the Kaplan-Meier method with cumulative incidence of relapse calculated using competing risks methodology. Baseline characteristics were compared using chi-squared or Mantel-Haenszel tests, with continuous variables compared using the Wilcoxon rank sum test. Time-to-event outcomes were compared using logrank tests and Cox regression. Outcomes are reported as effect sizes with 95% confidence intervals; significance was set at $p < .05$. Stratified analyses use stratified logrank tests and are displayed as Forest plots with tests for interaction using standard methodology²⁷. Comparison of transplantation versus not was analysed using the method of Mantel & Byar to mitigate immortal time bias.

Median follow-up for survival was 39.0 months (range 1.0-80.5 months).

Results

Induction Response by Morphology and MFC-MRD: Patient Characteristics

Between 2009 and 2014, 6539 samples (BM or PB at diagnosis, BM post treatment courses) from 2450 non-APML patients recruited to AML17 were prospectively analysed for flow cytometric detection of MRD (MFC-MRD) (Appendix-Fig A2). Among patients in complete remission post course-1 (C1), the presence of MRD data was associated with secondary AML, and the absence of an *NPM1* mutation (reflecting the prioritising of BM for RT-qPCR monitoring of *NPM1* mutations²³ during the second phase of the trial); survival at 5 years was 52% (with MRD data) vs 50% (without MRD data). In adjusted analyses, the presence of MRD data was not associated with survival (HR 0.99 (0.84-1.16) $P=0.9$).

Post-C1 1443 patients contributed data, 420 were refractory by morphology (197 resistant disease/ RD, 223 partial remission/ PR) and 1023 (70.9%) achieved morphological complete remission (CR/CRi) with MFC-MRD data (446 MFC-MRD negative [MRDneg], 577 MFC-MRD positive [MRDpos]). After the second course of induction (C2), 806 patients were in CR/CRi with MFC-MRD data (503 MRDneg, 303 MRDpos).

The clinical characteristics of patients according to response post-C1 and MRD status for patients in CR/CRi post-C1 or C2 are listed in Table 1. There was a significant association between responses post course-1 or course-2 and cytogenetic group; however, count recovery post course-1 was not significantly associated with MRD post either course.

Outcome Comparison for Morphologic Response and MFC-MRD Status after Course 1

We evaluated overall survival (OS) by C1 response status. Five year overall survival (OS) for all enrolled in AML17 excluding early deaths was 52% for those achieving CR/CRi vs 31% for refractory patients ($P<.001$). MRD status in CR/CRi versus PR or RD further differentiated 5 year survival outcomes (Fig 1A). A PR or MRDpos response gave intermediate survival at 5 years. Survival rates appeared equivalent between these two responses for the good / standard-risk patients; 5 year OS for MRDneg vs MRDpos vs PR vs RD were 63% vs 44% vs 35% vs 24% for all patients; 70% vs 51% vs 48% vs 27% when poor-risk patients excluded (Fig 1B); 66% vs 49% vs 46% vs 30% for standard-risk alone (Fig 1C) ($P<.001$ for all analyses). Similar results were observed for survival censored at SCT (Appendix-FigA3A, Fig 1D) and also for *NPM1*wild type (wt) standard-risk patients (Appendix-FigA3B-C).

Adjusted analyses confirmed significant survival differences between RD and PR / MRDpos but not between PR and MRDpos for good /standard-risk patients (RD vs PR /MRDpos, OS HR 2.28(1.38-3.75) $P=.0009$; PR vs MRDpos, HR=1.32, $P=0.4$) and for *NPM1*wt standard-risk patients (RD vs PR /MRDpos , OS HR 2.13(1.21-3.75) $P=.008$; PR vs MRDpos, HR=1.18, $P=0.6$) . Results were similar when censored at SCT (Table 2).

Thus the prognostic effect from morphological response criteria post first induction is restricted to RD in the good/ standard-risk subgroups when MFC-MRD status is incorporated into response assessment.

Only 25 patients were refractory by morphology post-C1 but MRDneg (22 PR, 3 RD) with 61% 3-year and 49% 5-year OS. Seven of 577 MRDpos patients were in morphological CR but had $\geq 5\%$ aberrant blasts by MFC (range 5.4-38%), Six died within 2 years, with one patient alive at 58.6 months.

Relative Prognostic Effect of MFC-MRD after Course 1 & Course 2 by Genetic / Risk Score Subgroup

In AML17 patients received 2 courses of induction regardless of remission status after course 1 but course 2 differed for patients designated as poor risk by trial risk score. Analyses of survival and relapse by MFC-MRD status of CR/CRi patients for C1 (n=1010) and C2 (n=803) were performed stratified by cytogenetic²⁸ and trial risk subgroups (Fig 2, Appendix-FigA4) to investigate the relative prognostic impact from clearance of blasts below MFC-MRD detection threshold at either of these response assessment time-points. There was some evidence that the benefit from MFC-MRD negativity on OS was lower in poor-risk patients compared to other subgroups with the NCRI AML17 treatment schedule (test for trend; p=0.01 for C1, p=0.05 for C2). Overall MFC-MRD status appeared more prognostic for relapse and OS at C2 (relapse, OR 1.88(1.50- 2.36), p<0.001; survival, HR 1.77(1.41-2.22) p<0.001) than C1 (relapse, HR 1.70(1.40- 2.06), p<0.001; survival, HR 1.50(1.23-1.84) p<0.001) although this difference diminished when C1 analysis was restricted to patients who received course 2 and survived at least 30 days post-C2 (relapse, HR 1.80(1.49-2.18) p<.0001; survival, HR 1.87 (1.52-2.29) p<.0001).

Outcome from Combined Course 1 Response status and Course 2 MFC-MRD status

In patients with response / MFC-MRD data for both C1 and C2 time points (n=693), C2 MFC-MRD positivity remained significant on OS and relapse when adjusting for C1 response (5 year survival, HR 1.79(1.38-2.32) P<.0001; relapse, HR 1.52(1.18-1.96) P=.001) (Fig 3). A small number of patients (n=24) patients converted from C1 MRDneg to C2 MRDpos, with a particularly poor prognosis (15 relapses, 13 deaths); one had adverse risk cytogenetics and 5 were *Flt3ITD* mutated (Appendix-Table A1). Patients who were MRDneg at both C1 and C2 had the best outcome (n=217, 67 relapses /57 deaths); of these 80.8% were good /standard-risk and 26.3% *NPM1*wt standard-risk (Appendix-Table A2).

MRD status combined with peripheral count recovery

We examined the additional prognostic effect from combining MRD status with response by peripheral count recovery post-C1 and C2 ([Appendix-Table A3](#)). The frequencies of CRi as best response in the total cohort were similar in MRDpos vs MRDneg patients post-C1 (9.3%vs 9.6%) and C2 (13.1%vs12.0%); CRi frequencies were not relatively increased in the *NPM1*wt standard-risk subgroup. C1 CRi was associated with significantly decreased 5 year OS for total (39% vs 53%, $p=.002$) and in MRDpos (19% vs 45%, $p=.001$) but not for MRDneg patients. MRDpos *NPM1*wt standard-risk-patients in CRi also had a lower OS at 5 years (25%vs 48%, $p=0.4$) although difference was not significant. The effect of CRi vs CR was smaller post-C2 although outcomes were still worst in CRi/MRDpos patients. The reduced survival associated with CRi was not due to increased relapse.

Outcome by MFC-MRD status for *NPM1*-wild type Standard-Risk Patients

Since it is possible that the most appropriate MFC-MRD cut-off level for discriminating outcome may differ between AML genetic subgroups, we compared the 5 year cumulative incidence of relapse for C1 MRDneg vs MRDpos $<0.1\%$ vs MRDpos $\geq 0.1\%$ by our assay in CBF-AML and *NPM1*-mutated as well as *NPM1*wt standard-risk patients. For CBF-AML and *NPM1*-mutated post C1 MRDpos at any level ($<0.1\%$ or $\geq 0.1\%$) significantly increased relapse ([Appendix-FigA5](#)). However in the *NPM1*wt standard-risk subgroup, low level MRDpos ($<0.1\%$) post-C1 did not alter relapse risk compared to MRDneg but was associated with a higher CIR when detected post-C2 ([Fig 4A](#)). MRDpos levels of $\geq 0.1\%$ detected in 35% and 13% *NPM1*wt standard-risk patients post-C1 and post-C2 respectively predicted a high probability of relapse (C1 3 year CIR 68%, C2 CIR 89%). MRD status post second induction was also significantly prognostic for survival; 33% for any level of MRD positivity vs 63% for MRDneg at 5 years (3 years 47% vs 69%, $P=.003$) ([Fig 4B](#)). Of the 204 *NPM1*wt standard-risk patients with C2 MRD data, 83 had an allograft (44 in CR1: 29 MRDneg, 15 MRDpos). When survival was censored at any SCT, rates of 5 year OS were 35% vs 88% (3 years 47% vs 88%, $P=.0005$) ([Appendix-FigA6](#)). We next investigated the effect of SCT in CR1 according to C2 MRD status in Mantel-Byar analyses; although numbers were small, results suggested that transplant might be considered in MRDpos (HR 0.72(0.31-1.69) but not MRDneg patients (HR 1.68(0.75-3.85); p -value for interaction $p=0.16$) ([Fig 4C](#)).

Discussion

Response to induction therapy is a powerful prognostic indicator in AML. There are however differing practices for the implementation of technologies that measure residual leukemia to assess response. Flow cytometry is often used to support the definition of CR by morphology; those centres with access to experienced laboratories including some trial groups have extended its use to define CR without MRD⁵. It has recently been reported that outcomes post

myeloablative SCT for patients with pre-transplant flow cytometric MRD below 5% resemble those with at least 5% blasts by morphology¹³. This and the similar event-free survival observed in ~80 pediatric patients with MRD positivity after first induction whether <5% or ≥ 5% blasts by morphology⁷ suggest that dichotomising patients by a 5% blast CR cut-off fails to capture some prognostic information. Our results confirm this. By incorporating flow cytometric MRD with established response criteria of partial remission and resistant disease distinct prognostic groups emerge post first course of standard induction for 5 year survival. Importantly the response subgroup with intermediate outcome comprises patients on either side of the current CR blast threshold, those with MRD positivity in CR and those who are refractory but clinically classified as a PR; both responses are associated with very similar 5 year survival, particularly in patients otherwise allocated as good /standard-risk subgroups. This is also the case when PR is defined by ELN criteria^{5,21}([Appendix-FigA7](#)). From this, 3 response categories post first induction could be proposed: resistant disease, partial responders (flow cytometric MRD-positive whether below or above 5% blast threshold) and CR/CRi without MRD. CRi was an independent risk factor to MRD in a study that included relapsed/refractory AML and differing induction intensities^{29,30}. From our data, outcomes for newly diagnosed AML patients achieving negative MRD are equivalent between CRi and CR after a single standard induction. However, the relatively few in our cohort (4.8%) with both CRi and MRD-positivity after first induction had as poor survival (OS 19% for all, 25% NPM1wt standard-risk) as RD patients.

For those completing a second induction with a CR/CRi, post course-2 MRD status increases prognostic discrimination. Although sample attrition bias may limit analyses comparing time-points, MRD negativity post course-2 improves outcome overall even when adjusting for slower blast clearance by course-1 response. This differs from our previous results in older adults¹⁷ and might reflect the better treatment tolerance and mutation profiles of younger adults. However following the second daunorubicin/cytosine arabinoside induction, ~33% of standard-risk /~34% of NPM1wt standard-risk patients in CR/CRi had persistent bone marrow MRD by our assay. Whether detectable MFC-MRD after completion of conventional induction is a sufficiently specific prognostic surrogate to guide therapy has been debated. The post-consolidation time-point was more informative in the GIMEMA study for a cohort that included ~70% with intermediate cytogenetics^{31,32}. This suggests that in a proportion of those with post-induction MRD positivity, consolidation may confer a favourable outcome by further MFC-MRD clearance (although it is of note that for some younger adults in the GIMEMA trials the induction/consolidation regime comprised 2 courses in total). Genetic profile, treatment intensity and the later effects of any transplant may also modify interpretation and utility of MFC-MRD to inform post-remission therapy. Our data is consistent with this since the prognostic impact as well as best MFC-MRD cut-off level differed between AML risk groups; MRD status appeared less discriminatory in the poor-risk

1 patients. Importantly however, in the NPM1wt standard-risk subgroup, detectable MFC-MRD at
2 $\geq 0.1\%$ early in treatment is associated with significantly higher relapse rates (89% after second
3 course). The ‘false negative’ 50% CIR observed for post induction MRD-negative NPM1wt
4 standard-risk patients could reflect MFC-MRD sensitivity limitations although a similar CIR was
5 observed for DNTM3A-mutated /NPM1-mutated patients who were MRD-negative by NPM1-
6 mutated transcript RT-qPCR²³. Exploratory analyses could not identify any significant clinical
7 parameters that predicted MRD-negative relapses. Longitudinal broad molecular studies may
8 disclose whether increased pre-leukemic instability re-initiating AML^{33,34} or persistence of pre-
9 treatment minor or major leukemic clones^{35,36} contributes to these ‘false-negative’ relapse risks.
10 Notwithstanding, NPM1wt standard-risk patients achieving MRD negativity post second induction
11 had a significantly better survival. As their survival increased to 88% when censored for transplant,
12 this raises the possibility that transplant in first remission could be avoided in this subset. The
13 Mantel-Byar analysis support this with some evidence of interaction, although this should be
14 interpreted cautiously as small numbers and the interaction was not significant.

15 Transplant decisions have mainly been arbitrary in this subgroup with no accepted approach to
16 distinguish those patients likely to be cured with chemotherapy alone (or those likely to be
17 successfully salvaged if they do relapse) from those who benefit from transplantation in first
18 remission or potentially experimental therapy. Our results suggest that allogeneic transplant in first
19 remission could be directed to those who are MRD-positive rather than MRD-negative. This is the
20 first indication that MRD status might have utility directing therapy for NPM1wt standard-risk
21 patients despite their molecular heterogeneity. Large patient data sets likely requiring collaborative
22 efforts will determine whether integrating MFC-MRD status with genomic profiles^{37,38} further
23 informs outcome prediction.

24 25 26 **Acknowledgements:**

27 We are grateful to NIHR and Cancer Research UK for research funding for this trial, to the staff of
28 the Haematology Trials Office, Cardiff Experimental Cancer Medicine Centre and reference
29 laboratories for supporting the trial, members of the NCRI AML working group and to our other co-
30 investigators, research nurses and participants who provided samples from the NCRI AML Trial
31 centres (listed in Supplementary Appendix).
32

33 34 35 **Author Disclosures**

36 37 **Author Contributions**

38 Conception and design: Alan Burnett, Sylvie Freeman, David Grimwade, Robert Hills, Nigel Russell
39 Provision of study patients and samples: Alan Burnett, Lars Kjeldsen, Nigel Russell, James D Cavenagh,
40 Gail Jones, Asim Khwaja, Paul Cahalin
41 Collection and assembly of data: Sylvie Freeman, Paul Virgo, Naeem Khan, Steve Couzens, Richard
42 Dillon, Amanda Gilkes, Laura Upton, Ian Thomas, Robert Hills

1 Data analysis and interpretation: Sylvie Freeman, Alan Burnett, Robert Hills, Nigel Russell
2 Manuscript writing: All authors except DG
3 Final approval of manuscript: All authors except DG

4

5 **Author Affiliations**

6 ¹Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, ²Centre for Trials
7 Research Cardiff University, Cardiff, ³North Bristol NHS Trust, Bristol, ⁴University Hospital of Wales, Cardiff,
8 ⁵King's College London School of Medicine, London, ⁶Experimental Cancer Medicine Centre, Cardiff
9 University, Cardiff, ⁷Department of Haematology, Rigshospitalet, Copenhagen, Denmark, ⁸Department of
10 Haematology, St Bartholomew's Hospital, Queen Mary University of London, ⁹Department of Haematology,
11 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, ¹⁰Department of Haematology,
12 University College London, ¹¹Department of Haematology, Blackpool Teaching Hospital NHS Foundation
13 Trust, Blackpool, [†]deceased author, ¹²Isle of Arran, ¹³Nottingham University Hospital, Nottingham, UK for
14 the UK National Cancer Research Institute AML Working Group
15

References

1. Wheatley K, Burnett AK, Goldstone AH, et al: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. *Br J Haematol* 107:69-79, 1999
2. Schlenk RF, Benner A, Hartmann F, et al: Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. *Leukemia* 17:1521-8, 2003
3. Kern W, Haferlach T, Schoch C, et al: Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. *Blood* 101:64-70, 2003
4. O'Donnell MR, Tallman MS, Abboud CN, et al: Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 15:926-957, 2017
5. Dohner H, Estey E, Grimwade D, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* 129:424-447, 2017
6. Bassan R: Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia. *J Clin Oncol* 34:300-2, 2016
7. Inaba H, Coustan-Smith E, Cao X, et al: Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. *J Clin Oncol* 30:3625-32, 2012
8. Loken MR, Alonzo TA, Pardo L, et al: Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. *Blood* 120:1581-8, 2012
9. Ouyang J, Goswami M, Tang G, et al: The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. *Am J Hematol* 90:504-10, 2015
10. Buccisano F, Maurillo L, Del Principe MI, et al: Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. *Blood* 119:332-41, 2012
11. Grimwade D, Freeman SD: Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? *Hematology Am Soc Hematol Educ Program* 2014:222-33, 2014
12. Ossenkoppele G, Schuurhuis GJ: MRD in AML: does it already guide therapy decision-making? *Hematology Am Soc Hematol Educ Program* 2016:356-365, 2016
13. Araki D, Wood BL, Othus M, et al: Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? *J Clin Oncol* 34:329-36, 2016
14. Hourigan CS, Goswami M, Battiwalla M, et al: When the Minimal Becomes Measurable. *J Clin Oncol* 34:2557-8, 2016
15. Hourigan CS, Gale RP, Gormley NJ, et al: Measurable residual disease testing in acute myeloid leukaemia. *Leukemia*, 2017
16. Buccisano F, Maurillo L, Spagnoli A, et al: Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. *Blood* 116:2295-303, 2010
17. Freeman SD, Virgo P, Couzens S, et al: Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. *J Clin Oncol* 31:4123-31, 2013
18. Othus M, Wood BL, Stirewalt DL, et al: Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. *Leukemia* 30:2080-2083, 2016
19. Ravandi F, Jorgensen J, Borthakur G, et al: Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. *Cancer* 123:426-435, 2017
20. Terwijn M, van Putten WL, Kelder A, et al: High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol* 31:3889-97, 2013
21. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol* 21:4642-9, 2003

22. Ferguson P, Hills RK, Grech A, et al: An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. *Haematologica* 101:1351-1358, 2016
23. Ivey A, Hills RK, Simpson MA, et al: Assessment of Minimal Residual Disease in Standard-Risk AML. *N Engl J Med* 374:422-33, 2016
24. Balsat M, Renneville A, Thomas X, et al: Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. *J Clin Oncol* 35:185-193, 2017
25. Burnett AK, Hills RK, Wheatley K, et al: A sensitive risk score for directing treatment in younger patients with AML Blood (ASH Annual Meeting Abstracts) 108, 2006
26. Ling V, Burnett AK, Bradstock K, et al: Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. *Br J Haematol* 160:861-3, 2013
27. Group EBCTC: Treatment of early breast cancer. 1. Worldwide evidence 1985-1990, Oxford University Press, USA, 1990
28. Grimwade D, Hills RK, Moorman AV, et al: Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. *Blood* 116:354-65, 2010
29. Chen X, Xie H, Estey EH: Reply to D. Przepiorka et al. *J Clin Oncol* 33:3676-7, 2015
30. Chen X, Xie H, Wood BL, et al: Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. *J Clin Oncol* 33:1258-64, 2015
31. Buccisano F, Maurillo L, Gattei V, et al: The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. *Leukemia* 20:1783-9, 2006
32. Maurillo L, Buccisano F, Del Principe MI, et al: Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. *J Clin Oncol* 26:4944-51, 2008
33. da Silva-Coelho P, Kroeze LI, Yoshida K, et al: Clonal evolution in myelodysplastic syndromes. *Nat Commun* 8:15099, 2017
34. Makishima H, Yoshizato T, Yoshida K, et al: Dynamics of clonal evolution in myelodysplastic syndromes. *Nat Genet* 49:204-212, 2017
35. Parkin B, Londono-Joshi A, Kang Q, et al: Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. *J Clin Invest* 127:3484-3495, 2017
36. Shlush LI, Mitchell A, Heisler L, et al: Tracing the origins of relapse in acute myeloid leukaemia to stem cells. *Nature* 547:104-108, 2017
37. Bullinger L, Dohner K, Dohner H: Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. *J Clin Oncol* 35:934-946, 2017
38. Gerstung M, Papaemmanuil E, Martincorena I, et al: Precision oncology for acute myeloid leukemia using a knowledge bank approach. *Nat Genet* 49:332-340, 2017

Figure Legends

Figure 1. Overall Survival according to post course 1 response status.

(A) all patients (B) good and standard risk patients (known poor risk excluded) (C) standard-risk patients (D) OS for standard-risk patients censored at allogeneic stem cell transplantation

RD, refractory disease; PR, partial remission; CR, complete remission; MRD, measurable residual disease; MRD-, MRD negative; MRD+, MRD positive; ASCT, allogeneic stem cell transplantation

Figure 2. Forest Plots for Overall Survival by MFC - MRD status for patients in CR (A) post course 1, (B) post course 2 stratified by cytogenetic risk group and NCRI AML17 risk score group

CR, complete remission; MRD, measurable residual disease; MRD -, MRD negative; MRD+, MRD positive

Figure 3. Forest Plots for (A) Overall Survival and (B) Relapse by combined post course 1 and 2 response data.

Effect of MFC-MRD status in CR post course 2 stratified by post course 1 response status

CR, complete remission; RD, refractory disease; PR, partial remission; MRD, measurable residual disease; MRD-, MRD negative; MRD+, MRD positive

Figure 4. Standard-risk *NPM1*-wild type: (A) Cumulative Incidence of Relapse (CIR) by MRD level

(MRD- vs MRD+ <0.1% vs MRD+ ≥ 0.1%) post course 1 and post course 2,

(B) Overall Survival according to post course 2 MRD status, MRD- vs MRD+.

(Not shown: MRD+ ≥ 0.1%, overall survival of 24%; MRD+ <0.1%, overall survival of 39%)

(C) Mantel Byar for survival according to CR1 SCT by MRD status post course 2

MRD, measurable residual disease; MRD-, MRD negative; MRD+, MRD positive

SCT, allogeneic stem cell transplant; CR1, first CR; MRD-, MRD negative; MRD+, MRD positive

In Appendix

Appendix Figure A1. Flow chart for treatments given to patients in NCRI AML17

Appendix Figure A2. CONSORT: Outline of patient sample flow for MRD study

Appendix Figure A3. OS according to post course 1 response status. (A) All patients, OS censored at allogeneic stem cell transplantation, (B) *NPM1* wild type standard risk patients, (C) *NPM1* wild type standard risk patients, censored at allogeneic stem cell transplantation

1 OS, overall survival; RD, resistant disease; PR, partial remission; CR, complete remission; MRD,
2 measurable residual disease; MRD-, MRD negative; MRD+, MRD positive; SCT, allogeneic stem
3 cell transplantation

4 [Appendix Figure A4](#). Forest Plots for Relapse by FCM - MRD status for patients in CR (A) post
5 course 1, (B) post course 2 stratified by cytogenetic risk group and NCRI AML 17 risk score group

6 CR, complete remission; MRD, measurable residual disease; MRD-, MRD negative; MRD+, MRD
7 positive

8 [Appendix Figure A5](#). Cumulative Incidence of Relapse (CIR) by MFC-MRD level

9 (MRD- vs MRD+ <0.1% vs MRD+ ≥ 0.1%) post course 1

10 (A) CBF AML (B) Standard Risk NPM1 Mutant

11 MRD, measurable residual disease; MRD-, MRD negative; MRD <0.1%, MRD positive <0.1%;

12 MRD 0.1%+, MRD positive ≥ 0.1%

13

14

15 [Appendix Figure A6](#). Standard Risk NPM1wild type: Overall Survival according to post course 2
16 FCM-MRD status, censored at any allogeneic stem cell transplantation

17 CR, complete remission; MRD, measurable residual disease; MRD-, MRD negative; MRD+, MRD
18 positive

19

20 [Appendix Figure A7](#). OS according to post course 1 response status applying ELN /Cheson
21 criteria for PR and RD instead of MRC criteria. **(A)** All patients. **(B)** good and standard risk
22 patients (known poor risk excluded) **(C)** standard risk patients, **(D)** standard risk patients, OS
23 censored at allogeneic stem cell transplantation.

24 OS, overall survival; RD, resistant disease by ELN definition; PR, partial remission by ELN

25 definition; CR, complete remission; MRD, measurable residual disease; MRD-, MRD negative;

26 MRD+, MRD positive; SCT, allogeneic stem cell transplantation

27 ELN criteria for PR: all hematologic criteria of CR; decrease of bone marrow blast percentage to

28 5% to 25% with decrease of pretreatment bone marrow blast percentage by at least 50%

29

30

31


32

33


34

FIGURE 1A - D


A Overall Survival All patients



B Overall Survival Excluding Poor Risk



C Overall Survival Standard Risk



D Overall Survival Standard Risk censored at SCT




Figure 2A: Effect of FCM-MRD status post course 1 stratified by cytogenetic and risk score group
Overall Survival




Figure 2B: Effect of FCM-MRD status post course 2 stratified by cytogenetic and risk score group
Overall Survival





Figure 3A: Combined post course 1 and 2 response status
Overall Survival



**Figure 3B: Combined post course 1 and 2 response status
Relapse**

MRD status in CR post C2






Figure 4

Standard Risk NPM1wt


A CIR by post course 1 FCM-MRD level



CIR by post course 2 FCM-MRD level



B Overall Survival by post course 2 FCM-MRD



C Mantel-Byar analysis of CR1 allograft in Standard Risk NPM1wt by post course 2 MRD




Table 1: Characteristics of Study Population by Response

	Post Course 1 Response (n= 1443)							Post Course 2 MRD status in CR (n= 806)		
	MRD- No. (%)	MRD+ No. (%)	PR No. (%)	RD No. (%)	P-value MRD- vs MRD+	P-value (4 categories)	P-value MRD+ vs PR	MRD- No. (%)	MRD+ No. (%)	P-value
All patients	446 (30.9%)	577 (40.0%)	197 (13.7%)	223 (15.5%)				503 (62.4%)	303 (37.6%)	
Age, years										
16-29	48 (10.8)	67 (11.6)	22 (11.2)	26 (11.7)				67 (13.3)	29 (9.6)	
30-39	59 (13.2)	55 (9.5)	15 (7.6)	24 (10.8)				64 (12.7)	33 (10.9.)	
40-49	104 (23.3)	135 (23.4)	36 (18.3)	39 (17.5)				122 (24.3)	62 (20.5)	
50-59	145 (32.5)	187 (32.4)	75 (38.1)	68 (30.5)				168 (33.4)	99 (32.7)	
60+	90 (20.2)	133 (23.1)	49 (24.9)	66 (29.6)				82 (16.3)	80 (26.4.)	
Median Age, years (range)	50 (16-71)	51 (16-72)	53 (16-72)	53 (17-73)	0.3**	0.02**	0.3**	49 (16-72)	53 (16-72)	0.002**
Sex					0.06	0.03*	1.0			.006
Female	220 (49.3)	250 (43.3.)	85 (43.1.)	91 (40.8.)				248 (49.3.)	119 (39.3.)	
Male	226 (50.7)	327 (56.7)	112 (56.9)	132 (59.2.)				255 (50.7.)	184 (60.7.)	
Diagnosis					0.007	0.0009	0.5			0.12
De Novo	410 (91.9.)	492 (85.3)	162 (82.2.)	193 (86.5.)				459 (91.3.)	265 (87.5.)	
Secondary	18 (4.0.)	52 (9.0.)	23 (11.7)	25 (11.2)				25 (5.0)	26 (8.6.)	
High risk MDS	18 (4.0)	33 (5.7)	12 (6.1)	0 (0)				19 (3.7)	12 (4.0)	
WHO Performance Status					1.0*	0.4*	0.8*			0.7*
0										
1	314 (70.4)	413 (71.6)	138 (70.1)	148 (66.4)				359 (71.4)	219 (72.3)	
2	115 (25.8)	138 (23.9)	53 (26.9)	65 (29.1)				124 (24.7)	72 (23.8)	
3	11 (2.5)	14 (2.4)	4 (2.0)	6 (2.7)				13 (25.8)	9 (3.0)	
4	5 (1.1)	12 (2.1)	2 (1.0)	4 (1.8)				6 (1.2)	3 (1.0)	
	1 (0.2)	0 (0)	0 (0)	0 (0)				1 (0.1)	0 (0)	
WBC (x10⁹/L)										
0-9.9	219 (49.1)	301 (52.2)	114 (57.9)	112 (50.2)				260 (51.7)	155 (51.2)	
10-49.9	156 (35.0)	186 (32.2)	47 (23.9)	55 (24.7)				166 (33.0)	88 (29.0)	
50-99.9	42 (9.4)	45 (7.8)	21 (10.7)	26 (11.7)				46 (9.1)	29 (9.6)	

100+	29 (6.5)	45 (7.8)	15 (7.6)	30 (13.5)				31 (61.6)	31 (10.2)	
Median WBC (x10 ⁹ /L) (range)	10.6 (0.3-319.6)	8.9 (0.4-456.0)	6.0 (0.4-430.0)	9.9 (0.6-430.0)	0.3**	0.3**	0.13**	9.3 (0.7-275.2)	9.5 (0.4-430.0)	0.5**
Cytogenetics					<.0001*	<.0001*	<.0001*			<.0001
Favorable	82 (18.4)	75 (13.0)	8 (4.1)	3 (1.3)				94 (18.7)	18 (5.9)	
Intermediate	322 (72.2)	386 (66.9)	126 (64.0)	130 (58.3)				349 (69.4)	208 (41.4)	
Adverse	27 (6.1)	87 (15.1)	53 (26.9)	79 (35.4)				36 (7.2)	59 (11.7)	
Unknown	15 (3.3)	28 (4.9)	10 (5.1)	11 (4.9)				24 (4.8)	17 (3.4)	
FLT3-ITD / NPM1c Status					.001	<.0001	0.05			0.005
ITD WT, NPM1c WT	229 (51.3)	356 (61.7)	129 (65.5)	174 (78.0)				274 (54.5)	192 (63.4)	
ITD WT, NPM1c mutant	99 (22.2)	88 (15.3)	18 (9.1)	8 (3.6)				102 (20.3)	39 (12.9)	
ITD mutant, NPM1c WT	22 (5.0)	42 (7.3)	17 (8.6)	29 (13.0)				27 (5.4)	24 (7.9)	
ITD mutant, NPM1c mutant	63 (14.1)	63 (10.9)	12 (6.1)	5 (2.2)				66 (13.1)	28 (9.2)	
Unknown	33 (7.4)	28 (4.9)	21 (10.7)	7 (3.1)				34 (6.8)	20 (6.6)	
Post-course 1 Response					0.9					<.0001*; CR vs CRi (p=0.8)
CR	407 (91.3)	528 (91.5)						412 (81.9)	219 (72.3)	
CRi	39 (8.7)	49 (8.5)						37 (7.4)	18 (5.9)	
PR								26 (5.2)	33 (10.9)	
RD								22 (4.4)	28 (9.2)	
								6 (1.2)	5 (1.7)	
Post-course 1 Risk Score					<.0001*	<.0001*	<.0001*			<.0001*
Good	86 (19.3)	85 (14.7)	11 (5.6)	3 (1.3)				102 (20.3)	30 (9.9)	
Standard	253 (56.7)	267 (46.3)	42 (21.3)	37 (16.6)				267 (53.1)	131 (43.2)	
Poor Risk	102 (22.9)	218 (37.8)	138 (70.1)	167 (74.9)				132 (26.2)	141 (46.5)	
Not Assessable	6 (1.3)	6 (1.0)	6 (3.0)	16 (7.2)				2 (0.4)	1 (0.3)	
Number of Chemotherapy Cycles (poor risk excluded)					n/a	n/a	n/a			n/a
3	95 (21.3)	128 (22.2)	12 (6.1)	0 (0)				113 (22.5)	64 (21.1)	
4	117 (26.2)	116 (20.1)	10 (5.1)	1 (0.4)				139 (27.6)	49 (16.2)	
Not Randomised	139 (31.2)	130 (22.5)	37 (18.8)	56 (25.1)				128 (25.4)	56 (18.5)	
Allogeneic SCT					0.07	0.0008*	0.01			0.04
Any	142 (31.8)	215 (37.3)	102 (51.8)	89 (39.9)				193 (38.4)	139 (45.9)	
CR1	82 (18.4)	128 (22.2)	75 (38.1)	71 (31.8)				114 (22.7)	91 (30.0)	

CR2	38 (8.5)	68 (11.8)	4 (2.0)	2 (0.9)				54 (10.7)	32 (10.6)	
-----	----------	-----------	---------	----------	--	--	--	------------	------------	--

Chi-square test unless specified otherwise. *: Mantel-Haenszel test for trend;**: Wilcoxon rank sum test/Spearman correlation; n/a not assessed as 3 v 4 courses randomised.

MRD, measurable residual disease by flow cytometry; MRD+, MRD positive; MRD- , MRD negative; CR, Complete Remission; CRi, complete remission with absolute neutrophil count <1,000/μl or thrombocytopenia <100,000/μ; RD, Resistant Disease (less than a 50% reduction in blast numbers with >15% residual blasts) PR, Partial Response (at least a 50% reduction in blast numbers with 5% -15% residual blasts

Table 2: Outcomes by post course 1 response status

	PR	MRD+ in CR	Unadjusted HR/OR, 95% CI; p-value	adjusted HR/OR, 95% CI; p-value	RD	PR or MRD+ in CR	Unadjusted HR/OR, 95% CI; p-value	adjusted HR/OR, 95% CI; p-value
All patients	N= 197	N= 577			N= 223	N= 774		
5yr (3yr) OS	35% (41%)	44% (51%)	1.50 (1.18-1.91) P=.001	1.32 (1.05-1.66) p=0.02	24% (30%)	41% (48%)	2.43 (1.93-3.06) p<.0001	1.61 (1.31-1.97) p<.0001
5yr (3yr) OS censored at SCT	41% (48%)	49% (54%)	1.81 (1.25-2.61) P=.002	1.62 (1.16-2.25) p=0.004	11% (11%)	48% (53%)	8.17 (5.76-11.6) p<.0001	2.64 (2.02-3.45) p<.0001
Good / Standard Risk patients	N= 53	N= 352			N= 40	N= 405		
5yr (3yr) OS	49% (58%)	51% (59%)	1.11 (0.69-1.76) P=0.7	1.320 (0.65-2.68) P=0.4	33% (33%)	51% (59%)	16.6 (9.24-30.0) P<.0001	2.28 (1.38-3.75) p=.0009
5yr (3yr) OS censored at SCT	67% (73%)	60% (66%)	1.05 (0.54-2.06) P=0.9	1.38 (0.68-2.80) P=0.4	37% (at 3, 4 yrs)	61% (67%)	22.4 (8.23-60.8) P<.0001	3.56 (1.78-7.12) p=.0002
Standard Risk NPM1 WT patients	N= 27	N= 149			N= 34	N= 176		
5yr (3yr) OS	38% (55%)	47% (55%)	1.10 (0.60-2.04) P=0.8	1.18 (0.61-2.28) P=0.6	28% (28%)	45% (55%)	3.09 (1.65-5.80) p=0.0004	2.13 (1.21-3.75) p=.008
5yr (3yr) OS censored at SCT	53% (71%)	52% (59%)	1.38 (0.52-3.63) P=0.5	1.51 (0.58-3.93) P=0.4	28% (at 3 yrs)	53% (60%)	18.2 (6.38-52.1) p<.0001	3.88 (1.68-8.94) p=0.001

PR , morphological partial response; CR, morphological complete remission; MRD+, MRD positive; CRi, complete remission with absolute neutrophil count <1,000/ μ l or thrombocytopenia <100,000/ μ l; OS – overall survival; SCT – allogeneic stem cell transplant; RFS– relapse free survival ; CIDCR – cumulative incidence of death in remission.

Adjusted analyses included age, wbc, sex, performance status, disease type (secondary or de novo) and cytogenetic group.

Appendix Table A1

karyotype	Cytogenetic risk group	NPM1 mutation	Flt3 ITD
46,XY,t(8;21)(q22;q22)[7]/47,idem,+8[3]	good	negative	negative
46,XY[20]	intermediate	NA	NA
46,XY[20]	intermediate	+	+
46,XY[20]	intermediate	+	+
46,XX[16]	intermediate	+	+
46,XX[20]	intermediate	negative	+
46,XY[20]	intermediate	negative	+
46,XX[20]	intermediate	+	negative
46,XY[20]	intermediate	negative	negative
46,XX[20]	intermediate	negative	negative
46,XX[20]	intermediate	negative	negative
46,XX[20]	intermediate	negative	negative
46,XX,t(11;19)(q23;p13.1)[10]	intermediate	negative	negative
46,XY,del(9)(q?2q?3)[9]/46,XY[2]	intermediate	negative	negative
46,XX,t(2;9)(p22;p21)[12]/46,XX[1]	intermediate	negative	negative
46,XY,t(6;9)(p23;q24)[9]/46,XY[1]	intermediate	negative	negative
46,XY[20]	intermediate	negative	negative
45,XX,dic(17;18)(p11.2;p11.2)[9]/46,XX[1]	intermediate	negative	negative
46,XX[20]	intermediate	negative	negative
46,XY[20]	intermediate	negative	negative
47,XY,+8[6]/ 46,XY[4]	intermediate	negative	negative
50,XY,+X,+4,t(10;11)(p12;q14),+15,+19[9]/ 46,XY[1]	adverse	negative	negative
Failed	NA	negative	negative
Failed	NA	negative	negative

Table A2: Correlation of Risk group and Clinical Response by combined C1 and C2 response status

	All	C1 MRD- C2 MRD-	C1 MRD- C2 MRD+	C1 MRD+ C2 MRD-	C1 MRD+ C2 MRD+	C1 PR C2 MRD-	C1 PR C2 MRD+	C1 RD C2 MRD-	C1 RD C2 MRD+
	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)	No. (%)
All (patients with both C1 and C2 data)	693	224 (32.3)	24 (3.5)	166 (24.0)	170 (24.5)	26 (3.8)	33 (4.8)	22 (3.2)	28 (4.0)
Post-course 1 Risk Score									
Good	110 (15.9)	48 (21.4)	2 (8.3)	34 (20.5)	19 (11.2)	2 (7.7)	3 (9.1)	1 (4.5)	1 (3.6)
Standard	347 (50.1)	133 (59.4)	15 (62.5%)	87 (52.4)	87 (51.2)	12 (46.2)	4 (12.1)	6 (27.3)	3 (10.7)
Poor Risk	234 (33.4)	41 (18.3)	7 (29.2)	45 (27.1)	64 (37.6)	12 (46.2)	26 (78.8)	15 (68.2)	24 (85.7)
Not Assessable	2 (0.3)	2 (0.9)	0	0	0	0	0	0	0
<i>NPM1</i> wt standard risk	180 (26)	59 (26.3)	10 (41.2)	50 (30.1)	43 (25.3)	8 (30.8)	4 (12.1)	6 (27.3)	3 (10.7)
Post-course 1 Response CR (excluding CRi/CRp) CRi / CRp	538 (77.6) 46 (6.6)	202 (90.2) 22 (9.8)	23 (95.8) 1 (4.2)	157 (94.6) 9 (5.4)	156 (91.8) 14 (14.4)				

C1, course 1 induction; C2, course 2 induction; MRD, measurable residual disease by flow cytometry; MRD+, MRD positive; MRD- , MRD negative; CR, Complete Remission; CRi, complete remission with absolute neutrophil count <1,000/ μ l or thrombocytopenia <100,000/ μ l; RD, Resistant Disease (less than a 50% reduction in blast numbers with >15% residual blasts; PR, Partial Response (at least a 50% reduction in blast numbers with 5% -15% residual blasts

Appendix Table A3 Outcomes for patients by peripheral count recovery response combined with MRD status

		No. (%CRi)	5 year (3 year) OS	p- value	5 year (3 year) CIR	p- value
All Patients	Post Course 1					
	CR vs CRi	933 / 88 (9.4%)	53% vs 39% (60% vs 46%)	0.002	50% vs 43% (46% vs 40%)	0.6
	MRD- CR vs MRD- CRi	407 / 39 (9.6%)	63% vs 63% (70% vs 63%)	0.2	40% vs 33% (35% vs 33%)	0.7
	MRD+ CR vs MRD+ CRi	526 / 49 (9.3%)	45% vs 19% (52% vs 33%)	0.001	58% vs 53% (54% vs 47%)	0.6
	Post Course 2					
	CR vs CRi	716 / 89 (12.4%)	54% vs 38% (59% vs 46%)	0.02	51% vs 47% (48% vs 44%)	0.9
	MRD- CR vs MRD- CRi	449 / 54 (12.0%)	63% vs 52% (68% vs 52%)	0.05	61% vs 57% (59% vs 57%)	0.9
	MRD+ CR vs MRD+ CRi	267 / 35 (13.1%)	37% vs 20% (46% vs 40%)	0.3	45% vs 40% (41% vs 36%)	0.9
Standard Risk NPM1 wt	Post Course 1					
	CR vs CRi	241 / 19 (7.9%)	52% vs 42% (64% vs 56%)	0.16	58% vs 66% (53% vs 66%)	0.2
	MRD- CR vs MRD- CRi	100 / 11 (11.0%)	60% vs 64% (77% vs 64%)	0.2	49% vs 66% (41% vs 66%)	0.07
	MRD+ CR vs MRD+ CRi	141 / 8 (5.7%)	48% vs 25% (55% vs 50%)	0.4	65% vs 69% (61% vs 69%)	0.8

	Post Course 2					
	CR vs CRi	180 / 24 (13.3%)	54% vs 47% (63% vs 47%)	0.3	58% vs 43% (55% vs 43%)	0.6
	MRD- CR vs MRD- CRi	118/ 16 (13.6%)	63% vs 61% (70% vs 61%)	0.6	52% vs 34% (48% vs 34%)	0.5
	MRD+ CR vs MRD+ CRi	62 /8 (12.9%)	35% vs 23% (50% vs 23%)	0.10	70% vs 67% (70% vs 67%)	0.7

MRD, measurable residual disease by flow cytometry; MRD+, MRD positive; MRD- , MRD negative; CR, Complete Remission; CRi, complete remission with absolute neutrophil count <1,000/μl or thrombocytopenia <100,000/μl;